Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Comparing the efficacy of tisa-cel and axi-cel in patients with R/R FL

Michael Dickinson • 11 Jun 2022
EHA 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel
ELARA ZUMA-5

In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, compares the safety and efficacy of tisagenlecleucel (tisa-cel) versus axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) follicular lymphoma (FL) based on data from two pivotal clinical trials: ELARA (NCT03568461) and ZUMA-5 (NCT03105336). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda

More from Michael Dickinson

4:18
Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Michael Dickinson • 16 Jun 2023
3:48
COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson • 16 Jun 2023
10:25
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Michael Dickinson et al. • 12 Dec 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals